Abstract:Highlights • Ferroptosis is a non-apoptotic cell death process with crucial roles in the progression of female-oriented cancers, including breast and gynecological malignancies. • Non-coding RNAs (ncRNAs), a diverse class of RNA transcripts that do not encode proteins, have emerged as key modulators of ferroptosis. • NcRNAs, especially microRNAs, long non-coding RNAs, and circular RNAs principally regulate the ferroptotic flux by controlling the expression of genes involved in lipid metabolism, oxidative stress, and cellular redox signaling pathways. • Over- and/or under-expression of these ncRNAs affects ferroptosis, promoting tumor growth, invasion, and metastasis in female-specific cancers. • Targeting these ncRNAs holds promise as a new therapeutic approach for counteracting the development and progression of female-specific malignancies. Ferroptosis, a recently identified type of non-apoptotic cell death, triggers the elimination of cells in the presence of lipid peroxidation and in an iron-dependent manner. Indeed, ferroptosis-stimulating factors have the ability of suppressing antioxidant capacity, leading to the accumulation of reactive oxygen species (ROS) and the subsequent oxidative death of the cells. Ferroptosis is involved in the pathophysiological basis of different maladies, such as multiple cancers, among which female-oriented malignancies have attracted much attention in recent years. In this context, it has also been unveiled that non-coding RNA transcripts, including microRNAs, long non-coding RNAs, and circular RNAs have regulatory interconnections with the ferroptotic flux, which controls the pathogenic development of diseases. Furthermore, the potential of employing these RNA transcripts as therapeutic targets during the onset of female-specific neoplasms to modulate ferroptosis has become a research hotspot; however, the molecular mechanisms and functional alterations of ferroptosis still require further investigation. The current review comprehensively highlights ferroptosis and its association with non-coding RNAs with a focus on how this crosstalk affects the pathogenesis of female-oriented malignancies, from breast cancer to ovarian, cervical, and endometrial neoplasms, suggesting novel therapeutic targets to decelerate and even block the expansion and development of these tumors. Graphical abstract Download : Download high-res image (117KB) Download : Download full-size image

Breast cancer secretes anti-ferroptotic MUFAs and depends on selenoprotein synthesis for metastasis

Targeting Ferroptosis in Breast Cancer

Integrated profiling uncovers prognostic, immunological, and pharmacogenomic features of ferroptosis in triple-negative breast cancer

Cell density-dependent ferroptosis in breast cancer is induced by accumulation of polyunsaturated fatty acid-enriched triacylglycerides

Ferroptotic Neutrophils Induce Immunosuppression and Chemoresistance in Breast Cancer

Ferroptosis heterogeneity within the tumor microenvironment revealed a genetic blueprint of breast cancer

Ribosome stalling during selenoprotein translation exposes a ferroptosis vulnerability in cancer

The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis

Ferroptosis: the emerging player in remodeling triple-negative breast cancer

Ferroptosis of tumour neutrophils causes immune suppression in cancer

Abstract P6-11-13: Ferroptosis Heterogeneity in Triple-Negative Breast Cancer Reveals an Innovative Immunotherapy Combination Strategy

Integrated Analysis of Single-Cell and Bulk RNA-Seq Data reveals that Ferroptosis-Related Genes Mediated the Tumor Microenvironment predicts Prognosis, and guides Drug Selection in Triple-Negative Breast Cancer

Metabolism of Selenium, Selenocysteine, and Selenoproteins in Ferroptosis in Solid Tumor Cancers

Abstract 6073: the Lipogenic Regulator SREBP Induces Transferrin in Circulating Melanoma Cells, Suppressing Their Susceptibility to Ferroptosis

The role of ferroptosis in breast cancer patients: a comprehensive analysis

Mitochondrial genome-encoded mitomiRs regulate cellular plasticity and susceptibility to ferroptosis in triple-negative breast cancer

Abstract 430: Precision diet and lipid modulating agents to induce lipid oxidation in breast cancer

Ferroptosis-enhanced Chemotherapy for Triple-Negative Breast Cancer with Magnetic Composite Nanoparticles.

Metabolic Intervention Nanoparticles for Triple‐Negative Breast Cancer Therapy via Overcoming FSP1‐Mediated Ferroptosis Resistance

Ferroptosis contributes to the progression of female-specific neoplasms, from breast cancer to gynecological malignancies in a manner regulated by non-coding RNAs: Mechanistic implications

Multienzyme-like Reactivity Cooperatively Impairs Glutathione Peroxidase 4 and Ferroptosis Suppressor Protein 1 Pathways in Triple-Negative Breast Cancer for Sensitized Ferroptosis Therapy.